More than 10 years have since passed and more and more innovative treatment details have been reached. Ipilimumab is a further example of what has been said. The use of a target agent that, through an indirect action on the immune system, shows antineoplastic activity against cancers such as melanoma, prostate cancer and NSCLC, was not even imaginable a few years ago. In March of this year FDA approved the ipilimumab in the treatment of advanced melanoma and in June it was published the positive results of the combination dacarbazine + ipilimumab as first line treatment of advanced melanoma. This could be considered the start of the combination approach in melanoma therapy.
Citation: Ascierto PA (2011) The Future of Melanoma Therapy is the Combination Approach. J Mol Biomark Diagn 2:102e.